Mayne enters US women’s health market with NASDAQ-listed partner for $205m; shareholders spookedIn a deal the company expects to be immediately material to its own revenues and profits, Australia’s Mayne Pharma (ASX:MYX) is entering the US women’s healthcare product market with NASDAQ-listed partner TherapeuticsMD. Executing a licencing agreement with Therapeutics, Mayne will hand the former $205.5m to fund the product-line acquisition.Payments to Therapeutics MD by Mayne will be made on sales-based milestones; for every US$100m in revenue made each year, Mayne will need to hand TherapeuticsMD $5m. Mayne will also pay royalties of US$3m a year for 12 years.
Mayne enters US women’s health market with NASDAQ-listed partner...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.08 |
Change
0.010(0.20%) |
Mkt cap ! $412.7M | |||
| Open | High | Low | Value | Volume |
| $5.05 | $5.08 | $5.02 | $395.8K | 78.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $5.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.08 | 3084 | 3 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| MYX (ASX) Chart |